--- title: "Organon & Co. (OGN) news: class action and merger" url: "https://aibio.space/companies/organon/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "OGN class action and merger news: Organon faces securities class action over dividend statements and a merger proxy suit. Organon & Co." --- OGN Organon & Co. NYSE · United States # Organon & Co. (OGN) news OGN class action and merger news Legal · 2026-07-31 ## [Organon faces securities class action over dividend statements and a merger proxy suit](https://aibio.space/news/organon-faces-securities-class-action-dividend-statements-merger-proxy/) Teamsters Local 710 leads a consolidated New Jersey class action against Organon and unnamed officers. Two derivative suits are stayed, and a July 6 suit against the board and Sun Pharma entities challenges the merger proxy. ## Latest Organon & Co. news 1. 2026-04-27 Mergers [Organon agrees to be acquired by Sun Pharma for $14.00 per share in cash](https://aibio.space/news/organon-agrees-acquired-sun-pharma-14-00-share-cash/) Organon agreed on April 26, 2026 to be bought by Sun Pharma for $14.00 a share in cash, a 103% premium to an April 9 close set before a media report. The company's enterprise value is $11.75 billion, and it carries $8.6 billion of debt. ## Organon & Co. at a glance - **Ticker**: OGN - **Listing**: NYSE - **Country**: United States - **Cash, Sep 30, 2026**: $1.46 billion ### Related companies - [Royalty Pharma](https://aibio.space/companies/royalty-pharma/) NASDAQ: RPRX - [Viatris](https://aibio.space/companies/viatris/) NASDAQ: VTRS - [Corbus Pharmaceuticals Holdings](https://aibio.space/companies/corbus-pharmaceuticals/) NASDAQ: CRBP - [MannKind](https://aibio.space/companies/mannkind/) NASDAQ: MNKD - [Neuphoria Therapeutics](https://aibio.space/companies/neuphoria-therapeutics/) NASDAQ: NEUP - [NovaBridge Biosciences](https://aibio.space/companies/novabridge-biosciences/) NASDAQ: NBP - [aTyr Pharma](https://aibio.space/companies/atyr-pharma/) NASDAQ: ATYR - [Merck & Company](https://aibio.space/companies/merck-mrk-nyse/) NYSE: MRK ### Also on NYSE - [SHOULDER INNOVATIONS, INC.](https://aibio.space/companies/shoulder-innovations/) SI - [WATERS CORP /DE/](https://aibio.space/companies/waters-de/) WAT - [Flyte Aviation](https://aibio.space/companies/flyte-aviation/) VJET - [Emergent BioSolutions](https://aibio.space/companies/emergent-biosolutions/) EBS - [Alto Neuroscience](https://aibio.space/companies/alto-neuroscience/) ANRO - [Rafael Holdings](https://aibio.space/companies/rafael/) RFL ## What Organon & Co. does Organon & Co. is a global healthcare company with a portfolio of over 70 products across women's health and general medicines, including biosimilars. Its women's health products are sold primarily for contraception and fertility, with key brands including Nexplanon, NuvaRing and Follistim AQ. Its biosimilars span oncology and immunology, including Ontruzant, Aybintio, Bildyos, Bilprevda, Brenzys, Renflexis, Hadlima and Tofidence. Its established brands include Emgality and Vtama cream 1%. Organon operates six manufacturing facilities in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom, and distributes products to patients in more than 140 countries and territories. In 2025 the company recorded revenues of $6.2 billion, with approximately 74% generated outside the United States. In January 2026 it divested the Jada System to Laborie Medical Technologies Corporation for up to $465 million. Nexplanon is a long-acting reversible contraceptive implant, and in January 2026 the FDA approved a five-year duration-of-use indication for it. | Product or program | What it is | Stage | |---|---|---| | Nexplanon (etonogestrel implant) | Long-acting reversible contraceptive implant | FDA approved five-year duration indication, January 2026 | | Ontruzant (trastuzumab-dttb) | Trastuzumab biosimilar in oncology | launched in more than 20 countries | | Bildyos (denosumab-nxxp) | Denosumab biosimilar | launched in the United States in 2025 | | Hadlima (adalimumab-bwwd) | Adalimumab biosimilar in immunology | launched in five countries | | Emgality (galcanezumab-gnlm) | Established brand in the cardiovascular, respiratory, dermatology and pain portfolio | | | Vtama (tapinarof) cream 1% | Established brand for dermatology | | Summarised from the company's [10-K filed Feb 24, 2026](https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/ogn-20251231.htm). ## Organon & Co. annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$6.22 billion](https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/) | [$6.40 billion](https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/) | | Net income (loss) | [$187.0 million](https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/) | [$864.0 million](https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/) | | Cash from operations | [$700.0 million](https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/) | [$939.0 million](https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/) | | Cash and equivalents | [$574.0 million](https://www.sec.gov/Archives/edgar/data/1821825/000182182526000004/) | [$675.0 million](https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $1.46 billion. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Organon & Co. Is there a class action against Organon & Co.? Our latest story on this, dated Jul 31, 2026: "Organon faces securities class action over dividend statements and a merger proxy suit". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/organon-faces-securities-class-action-dividend-statements-merger-proxy/). Is Organon & Co. involved in a merger or acquisition? Our latest story on this, dated Jul 31, 2026: "Organon faces securities class action over dividend statements and a merger proxy suit". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/organon-faces-securities-class-action-dividend-statements-merger-proxy/). What is the ticker symbol of Organon & Co.? Organon & Co. trades under the ticker OGN on NYSE. Where is Organon & Co. listed? Organon & Co. is listed on NYSE. Our directory also records these other listings: BMV:OGN; EUROTLX:4OGN; GETTEX:7XP; LSE:0A9W; LSX:A3CPKP. What is the SEC CIK of Organon & Co.? The SEC Central Index Key (CIK) for Organon & Co. is 1821825. Its filings are on SEC EDGAR. How many shares does Organon & Co. have outstanding? 262,609,433 shares as of 2026-07-24, per the cover page of its 10-Q filed 2026-07-31. Which country or territory is Organon & Co. listed under? Our directory records Organon & Co. under United States. What does Organon & Co. do? Our directory classifies Organon & Co. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Organon & Co.? The ISIN recorded for Organon & Co. is US68622V1061. Does aibio.space cover Organon & Co.? aibio.space lists Organon & Co. among 2,820 public biotech companies and publishes its news here as stories appear. What does Organon & Co. develop? Organon & Co. is a global healthcare company with a portfolio of over 70 products across women's health and general medicines, including biosimilars. Its women's health products are sold primarily for contraception and fertility, with key brands including Nexplanon, NuvaRing and Follistim AQ. What is Nexplanon (etonogestrel implant) from Organon & Co.? Nexplanon (etonogestrel implant): Long-acting reversible contraceptive implant Stage: FDA approved five-year duration indication, January 2026. What is Ontruzant (trastuzumab-dttb) from Organon & Co.? Ontruzant (trastuzumab-dttb): Trastuzumab biosimilar in oncology Stage: launched in more than 20 countries. What was Organon & Co.'s revenue last year? $6.22 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Organon & Co. profitable? Organon & Co. reported net income of $187.0 million for the fiscal year ended Dec 31, 2025, and generated $700.0 million of cash from operations, per its annual report to the SEC. ## Investor discussion: Organon & Co. Members talk about Organon & Co. (OGN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Organon & Co., newest first. Each line links the filing it comes from. 1. 2026-05-04 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1821825/000162828026029532/ogn-20260331.htm) 2. 2026-04-27 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1821825/000119312526178718/d38652dex991.htm) 3. 2025-08-06 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1821825/000182182525000066/ogn-20250630.htm) 4. 2024-10-31 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1821825/000110465924112866/tm2427187d1_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:OGN on TradingView](https://www.tradingview.com/symbols/NYSE-OGN/). ## SEC filings and registration - **SEC name**: Organon & Co. - **CIK**: 1821825 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: OGN (NYSE) - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 30 HUDSON STREET, JERSEY CITY, NJ, 07302 - **Phone**: 551-430-6000 - **Shares outstanding**: 262,609,433 as of 2026-07-24 (10-Q filed 2026-07-31) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1821825/000110465926089008/tm2621744d1_8k.htm) filed 2026-07-31 - [10-Q](https://www.sec.gov/Archives/edgar/data/1821825/000162828026051230/ogn-20260630.htm) filed 2026-07-31 - [8-K](https://www.sec.gov/Archives/edgar/data/1821825/000119312526314587/d128953d8k.htm) filed 2026-07-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1821825/000119312526307767/d88294d8k.htm) filed 2026-07-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1821825/000110465926072953/tm2617690d1_8k.htm) filed 2026-06-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1821825/000162828026029532/ogn-20260331.htm) filed 2026-05-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1821825/000110465926052165/tm2613165d1_8k.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1821825/000119312526178718/d38652d8k.htm) filed 2026-04-27 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001821825), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Organon & Co. is a public biotech or pharmaceutical company listed on NYSE under the ticker OGN, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Organon & Co. - **Ticker**: OGN - **Listing**: NYSE - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US68622V1061 - **Other listed symbols**: BMV:OGN; EUROTLX:4OGN; GETTEX:7XP; LSE:0A9W; LSX:A3CPKP - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NYSE-OGN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/organon/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Organon & Co. (OGN) news: class action and merger", 2026-10-31, https://aibio.space/companies/organon/